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Abstract
The neuropeptide calcitonin gene-related peptide (CGRP), expressed by nociceptive sensory
afferents in joints, is an important mediator in the pathogenesis of arthritis. Capsaicin causes neurons
in the dorsal root ganglia (DRG) to release CGRP from their central and/or peripheral axons,
suggesting a functional link between CGRP and the capsaicin receptor TRPV1. The expression of
both TRPV1 and CGRP have been reported to increase in several models of arthritis but the specific
involvement of TRPV1-expressing articular afferents that can release CGRP remains unclear. We
here wanted to ascertain whether the increase in the number of CGRP-positive primary afferents
during arthritis may be affected by genetic deletion of TRPV1. For this, we quantified the expression
of CGRP in primary afferent neurons in DRG in wild type mice (WT) vs. TRPV1-KO mice with
adjuvant-induced arthritis (AIA), using immunohistochemistry. We found that the fraction of DRG
neurons that were immunopositive for CGRP 1) was higher in naïve TRPV1-KO mice than in naïve
WT mice, 2) increased progressively 3–21 days after induction of AIA, and 3) this increase was
bilateral but significantly greater on the CFA-injected side than on the IFA-injected side in TRPV1-
KO mice. The increased expression of CGRP in AIA may reflect a phenotypic switch of primary
afferents from non-peptidergic to peptidergic and the larger increase in TRPV1-KO mice may
represent a plastic change to compensate for the missing receptor in a major sensory circuit.
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1. Introduction
The neuropeptide calcitonin gene-related peptide (CGRP), a marker for peptidergic nociceptive
afferents (Lawson et al., 2002), is an important mediator in the pathogenesis of arthritis
(Schaible et al., 2002). CGRP has been shown in articular afferents at the level of the dorsal
root ganglia (DRG, O’Brien et al., 1989) and in peripheral nerve fibers in normal and arthritic
joints (Donaldson et al., 1992; Larsson et al., 1991; Sluka and Westlund, 1993). Fine articular
afferents may not only mediate the slow burning pain reported by arthritic patients but, through
the release of CGRP into the joint, may facilitate inflammation and angiogenesis (Ferrell et
al., 1997; Konttinen et al., 1994), two closely related pathogenetic components of arthritis that
are the key determinants of disease progression (Bonnet and Walsh, 2005). In experimental
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arthritis, the release of CGRP into the joint is increased (Ahmed et al., 1995a) and CGRP gene
knockout mice (CGRP-KO) have reduced behavioral pain responses, consistent with a pro-
inflammatory and pro-nociceptive role for CGRP in joint inflammation (Zhang et al., 2001).
CGRP is expressed by C- and Aδ-fiber primary afferents, the majority of which express the
vanilloid receptor TRPV1 (Guo et al., 1999). TRPV1, a non-selective cation channel, is
important for thermal nociception and inflammatory hyperalgesia and allodynia (Caterina et
al., 1997). In vitro, TRPV1-expressing cells can be activated by noxious heat as well as by
vanilloids, including capsaicin. In mice, knocking out the TRPV1 gene prevented the
occurrence of thermal hyperalgesia in an experimental model of hindpaw inflammation
(Caterina et al., 2000; Davis et al., 2000). TRPV1-KO mice have thus been used to study the
involvement of capsaicin-sensitive sensory afferents in several models of painful inflammatory
conditions, including arthritis (Bolcskei et al., 2005); we and others have found that the severity
of adjuvant-induced arthritis (AIA) is significantly reduced in TRPV1-KO mice (Barton et al.,
2006; Chen et al., 2008; Szabo et al., 2005).
Noxious stimulation causes capsaicin-sensitive DRG neurons to release CGRP from their
central and/or peripheral axons (Averbeck and Reeh, 2001; Bernardini et al., 2004; Nanayama
et al., 1989), suggesting a functional link between CGRP and TRPV1, the receptor for
capsaicin. This is further supported by observations that the peripheral CGRP release is reduced
in TRPV1-KO mice and that blockade of the CGRP receptor abolishes TRPV1-mediated
effects on the circulatory system (Wang et al., 2006a; Wu et al., 2006). Furthermore, mice were
shown to exhibit variable sensitivity to noxious heat proportional to the level of genetic
expression of CGRP (Mogil et al., 2005). In a recent study using CGRP-KO and TRPV1-KO
mice, Szabo et al. (2008) reported that the protective role of CGRP in a model of scleroderma,
a disease that shares common pathogenetic mechanisms with rheumatoid arthritis, is mediated
by TRPV1.
Both CGRP and TRPV1 expression in DRG has been reported to increase in a rat model of
arthritis (Fernihough et al., 2005; Staton et al., 2007). Moreover, pretreatment with capsaicin
was found to mitigate the upregulation of CGRP in the rat AIA model (Ahmed et al., 1995b),
supporting previous observations that capsaicin reduces the expression of neuropeptides in
AIA (Levine et al., 1986), and suggesting that the effect may be mediated by capsaicin-sensitive
afferents. However, the mechanism through which TRPV1 participates in the pathogenesis of
arthritis and the specific involvement of TRPV1-expressing articular afferents that can release
CGRP remains unclear. The goal of the present study was to ascertain whether the increase in
the number of CGRP-positive primary afferents during arthritis is affected by the genetic
deletion of TRPV1. For this, we quantified the expression of CGRP in primary afferent neurons
in TRPV1-KO mice vs. wild type mice with AIA, using immunohistochemistry.
2. Materials and methods
2.1. Animal model, euthanasia and tissue handling
A total of 32 male mice, ages 4–6 months and weighing 25–30 g, were used in this study. These
included 16 each of TRPV1-KO and wild-type C57BL/6 mice (WT, Jackson Labs, Bar Harbor,
ME). All experimental procedures involving mice were carried out in compliance with the
National Research Council’s Guide for the Care and Use of Laboratory Animals, and according
to a protocol approved by the Institutional Animal Care and Use Committee at University of
North Carolina.
For AIA, mice were lightly anesthetized with a mixture of ketamine and xylazine (90 mg/kg
and 10 mg/kg, i.p.) and injected with 10 μl of complete Freund’s adjuvant (CFA, 20 mg/ml
suspension of heat-killed Mycobacterium tuberculosis in vehicle, Difco Lab, Detroit, MI) in
Chen et al. Page 2













each of two sites, front and back of the left ankle, using a 30-gauge needle attached to a 10 μl
Hamilton syringe. The right ankle of each mouse was injected with the same volume of vehicle
(paraffin oil containing mannide monooleate; Freund’s incomplete adjuvant, IFA). Matching
numbers of TRPV1-KO and WT mice were sacrificed at 3d (n=4), 7d (n=4), 14d (n=8), and
21d (n=12) after induction of arthritis; two each of TRPV1-KO and WT mice without injections
were sacrificed for collecting data in naïve animals.
For tissue collection, mice under deep anesthesia with sodium pentobarbital (80 mg/kg, i.p.)
were perfused intracardially with 30 ml freshly prepared solution of 1% paraformaldehyde in
0.1 M phosphate buffer, pH 7.4 (PB), followed by 100 ml solution of 4% paraformaldehyde
in PB. L4-L5 DRG bilaterally were dissected out, postfixed in 4% paraformaldehyde for 4
hours, cryoprotected in 30% sucrose in PB for 24–48 hours, and sectioned on a cryostat at 10
μm.
2.2. Immunohistochemistry
For immunohistochemistry, sections were permeabilized with 0.1% Triton X-100 in
phosphate-buffered saline (PBS; 0.01 M, pH 7.4) for 15 minutes, blocked with 5% normal
donkey serum in 0.1% Triton X-100 in PBS (NDS; Jackson Immunoresearch, West Grove,
PA) for 30 minutes, and incubated overnight with a guinea pig anti-CGRP antibody (1:2,000,
Peninsula, San Carlos, CA) in NDS. After several rinses with PBS and incubation with 5%
NDS for 30 minutes, sections were incubated with donkey anti-guinea pig antibody (1:200;
Jackson) for 2 hours, rinsed, and coverslipped with Vectashield (Vector, Burlingame, CA).
Digital micrographs were obtained with a Retiga EX cooled CCD camera (Q-Imaging, Surrey,
CA) attached to a Leitz DMR fluorescent microscope (Leitz, Wetzlar, Germany) and saved as
TIFF files; contrast and brightness were adjusted with Photoshop CS2 (Adobe Systems, San
Jose, CA). The primary antibody employed here was characterized and its selectivity was
confirmed using Western blots and preadsorption with CGRP, and is in common use in our
laboratory. As a routine control, we processed sections according to the above protocol, except
that primary or secondary antibodies were omitted; omission of primary or secondary
antibodies completely abolished specific staining.
2.3. Quantification and statistical analysis
Digital images were analyzed using Image J 1.38x software (NIH, Bethesda, MD). All counts
and measurements were performed by an investigator blinded to the source material, including
the genotype of the mouse and the side. Twelve DRG sections were analyzed per side per
mouse (4–8 sections of each of L4 and L5 ganglia, 60 μm apart); neuronal profiles (NP) were
identified by their typical cellular morphology. The cut-off brightness level (labeling density
threshold) was determined by averaging the integral brightness of three NP per section that
were judged to be minimally positive. All profiles whose mean labeling density exceeded this
threshold were counted as positive. The “background” immunofluorescence was high enough
to allow visualization of immunonegative NP, in some cases these were verified on images
acquired with DIC optics. The fraction of immunopositive NP in each section were expressed
as a percentage of total counted NP [% = (positive NP/total counted NP) × 100]. Data were
analyzed with SPSS 11.5x (SPSS, Chicago, IL) and graphed using Kaleidagraph (Synergy
Software, Reading, PA). Differences between animal groups were studied for significance with
one-way analysis of variance (ANOVA), which assessed the overall influence of genotype,
side (left, CFA-injected or right, IFA-injected), and time after induction of arthritis as main
factors, followed by a post hoc general contrast comparison using Tukey’s test. Significance
was set at p<0.05.
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In material from all mice, multiple NP and axons in the DRG and dense terminal fibers in the
superficial laminae of the spinal dorsal horn were immunostained for CGRP. In DRG of mice
with AIA, the number of stained NP appeared greater on the CFA-injected side than on the
IFA-injected side (Fig. 1). Counts in DRG at L4-L5 revealed that in uninjected (naïve) WT
mice, 32.6±0.9% (mean value ± standard error of the mean, time point “0” in Fig. 2) of all NP
were CGRP-positive; in naïve KO mice this percentage was significantly greater (41.6±0.5%).
After induction of AIA, the level of expression of CGRP was significantly greater in TRPV1-
KO than in WT mice on the CFA-injected (51.3±1.5% vs. 39.6±1.0% after 3 days, 59.4±1.8%
vs. 48.0±1.3% after 7 days, and 61.3±1.0% vs. 54.5±0.8% after 14 days, comparative data with
mean difference at the .05 level of significance are listed here, all data are graphed in Fig. 2).
On the IFA-injected side, expression of CGRP was also greater in TRPV1-KO than in WT
mice (48.8±1.4% vs. 38.7±1.3% after 3 days, 52.8±2.5% vs. 44.4±1.1% after 7 days, and 56.6
±0.8% vs. 50.1±0.8% after 14 days).
Thus, AIA caused bilateral increase in the fraction of CGRP-positive NP in DRG in both WT
and KO mice. This increase was more pronounced during the early stages of AIA and appeared
to plateau between days 7 and 14. Although naïve KO mice had a higher fraction of CGRP-
positive NP than naïve WT mice, 3 and 7 days after induction of AIA, the trend of increase in
the level of expression of CGRP was similar in the two groups on both CFA and IFA sides
(the curves of increase with time are roughly parallel). At the later stages of arthritis, both the
rate of increase and the differences between KO and WT mice were smaller at day 14 and
insignificant at day 21. However, at both 7 and 14 days, the increase on the CFA-injected side
over the IFA-injected side was greater in KO mice (59.4±1.8% vs. 52.8.0±2.5% after 7 days,
and 61.3±1.0% vs. 56.6±0.8% after 14 days) than in WT mice (Fig. 2).
4. Discussion
The main findings of this study are that the fraction of DRG neurons that were immunopositive
for CGRP 1) was higher in naïve TRPV1-KO mice than in naïve WT mice, 2) increased
progressively 3–21 days after induction of AIA, and 3) this increase was bilateral but
significantly greater on the CFA-injected side than on the IFA-injected side in TRPV1-KO
mice.
We here report for the first time that TRPV1-KO mice have higher levels of expression of
CGRP in primary afferents than WT mice, presumably reflecting a compensatory change
during development. The percentage of CGRP-positive DRG neurons in naïve WT mice in the
present study is in general agreement with the published data in C57BL6 mice (30%, (Zwick
et al., 2002) and BALB/c mice (27%, Robinson et al., 2004). We also reported previously that
of all articular afferents from the mouse ankle, identified by retrograde axonal tracing, 44%
immunostained for CGRP and 31% co-stained for CGRP and TRPV1 (Cho and Valtschanoff,
2008). In the rat, 25% of trigeminal afferents that innervate the temporomandibular joint
express TRPV1 and 73% of them coexpress CGRP (Ichikawa et al., 2004). In addition, the
expression of CGRP in articular afferents of naïve C57BL6 mice has been found to increase
with age: Salo et al. (2002) reported that 22% of knee afferents in young mice expressed CGRP,
in older mice, this number increased to 31% at 52 weeks and to 33% by 96 weeks, whereas the
expression of TRPV1 decreased with age (Wang et al., 2006b).
In mice with AIA, the changes in expression of CGRP in DRG and spinal cord correlated with
the severity of arthritis, as verified by behavioral and histopathological assessment (Chen et
al., 2008). In particular, the immunostaining for CGRP in DRG reaching its maximum at 14
days and then beginning to decline is analogous to the expression of the nociceptive marker p-
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ERK and the temporal pattern of change in the pain hypersensitivity observed in these mice
(Chen et al., 2008). This is also in agreement with the observation that the level of angiogenesis
(a major pathogenetic component of arthritis, see Introduction) in rats increased 14 days after
induction of osteoarthritis and then decreased to control levels by day 28 (Mapp et al., 2008).
The bilateral increase of CGRP in DRG that we observed in mice with AIA may reflect the
arthritogenic potential of IFA (Cannon et al., 1993) and/or the ability of CFA, when injected
in one joint, to evoke systemic inflammation and arthritis in the contralateral joint (Kelly et
al., 2007).
In a rat model of arthritis, the fraction of CGRP-positive neurons was reported to increase from
46% to 86% of identified knee afferents in L4 DRG (Fernihough et al., 2005) and from 45%
to 66% (Ochiai et al., 2007); the fraction of TRPV1-positive neurons also increased from 54%
to 78% in this model. Upregulation or de novo expression of CGRP in sensory neurons may
represent one mechanism of pain hypersensitivity in arthritis (Staton et al., 2007). The
behavioral response of arthritic CGRP-KO mice was antinociceptive, suggesting that the
release of CGRP plays a significant role in the central sensitization in these animals (Zhang et
al., 2001).
Upregulation of CGRP may occur in parallel with the increase in expression of TRPV1 in DRG
neurons (Amaya et al., 2003; Aoki et al., 2004) or in the peripheral nerve fibers at the site of
inflammation (Carlton and Coggeshall, 2001; Yiangou et al., 2001). Also in parallel with
TRPV1, the changes in CGRP expression may be bilateral and may depend on the particular
model of arthritis, survival time, and animal species (Bar et al., 2004).
That CGRP-positive articular afferents co-express TRPV1 (Cho and Valtschanoff, 2008) is
consistent with the possibility that synovial release of CGRP in the course of arthritis (Lotz et
al., 1987; Saito and Koshino, 2000) is triggered by depolarization of these afferents via TRPV1.
We showed in the rat that TRPV1-positive primary afferents, the majority of which co-express
CGRP, contact ascending nociceptive neurons in the spinal dorsal horn (Hwang et al., 2004)
and trigeminal dorsal horn (Bae et al., 2004). Perhaps these are the same neurons in the
superficial dorsal horn that express the CGRP receptor (Cottrell et al., 2005) and may thus be
targets for centrally-released CGRP. Whether the increased immunostaining for CGRP in
TRPV1-KO mice represents an overexpression of the peptide, whether this translates into an
increased central release of CGRP in arthritis, and whether it reflects an attempt at functional
compensation for the missing TRPV1 in the same or a parallel afferent input channel to the
spinal nociceptive neurons, remains to be established. The issue could be addressed by a
functional study using knockout mice and/or pharmacologic antagonists.
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Immunofluorescent staining for CGRP in DRG from sections of wild type (WT) and TRPV1-
KO mice: the number of labeled neuronal profiles appears greater on the CFA-injected side
than on the IFA-injected side 21 days after induction of AIA. In every group (WT and TRPV1-
KO), the sections of are from the left and right L5 DRG of the same mouse. Scale bar, 100
μm.
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The expression of CGRP was higher in TRPV1-KO (KO) than in wild type (WT) mice with
AIA: the fraction (mean ± standard error of the mean) of immunostained neuronal profiles was
higher in naïve KO mice than in naïve WT mice (time point “0”), increased progressively 3–
21 days after induction of AIA, and at days 7 and 14, was significantly greater on the CFA-
injected side than on the IFA-injected side in TRPV1-KO mice.
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